William Blair Investment Management LLC Reduces Stake in ANI Pharmaceuticals, Inc. $ANIP

William Blair Investment Management LLC reduced its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 28.9% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 348,680 shares of the specialty pharmaceutical company’s stock after selling 141,856 shares during the quarter. William Blair Investment Management LLC’s holdings in ANI Pharmaceuticals were worth $31,939,000 as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of ANIP. GAMMA Investing LLC increased its position in shares of ANI Pharmaceuticals by 9.1% during the 3rd quarter. GAMMA Investing LLC now owns 1,505 shares of the specialty pharmaceutical company’s stock valued at $138,000 after purchasing an additional 126 shares during the last quarter. Illinois Municipal Retirement Fund boosted its stake in ANI Pharmaceuticals by 1.7% during the third quarter. Illinois Municipal Retirement Fund now owns 8,538 shares of the specialty pharmaceutical company’s stock worth $782,000 after buying an additional 145 shares during the period. Amalgamated Bank increased its position in ANI Pharmaceuticals by 3.1% during the third quarter. Amalgamated Bank now owns 5,066 shares of the specialty pharmaceutical company’s stock valued at $464,000 after acquiring an additional 154 shares during the last quarter. CANADA LIFE ASSURANCE Co raised its stake in shares of ANI Pharmaceuticals by 1.0% in the second quarter. CANADA LIFE ASSURANCE Co now owns 19,408 shares of the specialty pharmaceutical company’s stock valued at $1,267,000 after acquiring an additional 198 shares during the period. Finally, Hantz Financial Services Inc. lifted its holdings in shares of ANI Pharmaceuticals by 202.6% in the 3rd quarter. Hantz Financial Services Inc. now owns 354 shares of the specialty pharmaceutical company’s stock worth $32,000 after acquiring an additional 237 shares during the last quarter. 76.05% of the stock is owned by institutional investors.

Insider Buying and Selling at ANI Pharmaceuticals

In other news, Director Renee P. Tannenbaum sold 1,800 shares of the company’s stock in a transaction that occurred on Friday, December 5th. The shares were sold at an average price of $81.15, for a total value of $146,070.00. Following the completion of the sale, the director owned 25,157 shares of the company’s stock, valued at approximately $2,041,490.55. This represents a 6.68% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Christopher Mutz sold 5,323 shares of the stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $78.02, for a total transaction of $415,300.46. Following the transaction, the insider owned 84,840 shares in the company, valued at approximately $6,619,216.80. This represents a 5.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 13,459 shares of company stock worth $1,066,611. 12.70% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the stock. Guggenheim lifted their price target on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the stock a “buy” rating in a research note on Friday, January 16th. Zacks Research cut ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 6th. Barclays began coverage on ANI Pharmaceuticals in a research note on Tuesday, December 9th. They set an “overweight” rating and a $100.00 price target for the company. Finally, Weiss Ratings reaffirmed a “hold (c+)” rating on shares of ANI Pharmaceuticals in a research report on Monday, December 29th. Six research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $103.43.

ANI Pharmaceuticals Trading Down 4.2%

Shares of NASDAQ ANIP opened at $73.90 on Monday. ANI Pharmaceuticals, Inc. has a twelve month low of $56.71 and a twelve month high of $99.50. The firm has a market cap of $1.66 billion, a PE ratio of 21.99 and a beta of 0.52. The business has a fifty day simple moving average of $80.19 and a two-hundred day simple moving average of $86.36. The company has a quick ratio of 2.19, a current ratio of 2.71 and a debt-to-equity ratio of 1.11.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.